Late yesterday Accolade (ACCD) announced it was diving deeper into the telehealth market by acquiring 2nd.MD, a small start-up based in Houston, TX. The acquisition target provides expert medical consultation services to patients, typically at a critical point in the patients’ lives when a second and/or...
Read More
Karyopharm (KPTI) pre-announced Q4 2020 results yesterday morning and I watched the stock, which was weak (closed down 8%) throughout the day as I pondered the results. I’ll get to my thoughts in a minute. First, the numbers.
Read More
Yesterday after the close Accolade (ACCD) reported Q3 results that surpassed expectations on both the top and bottom lines.
Read More
Tyler updates us on one more stock that reported earnings recently.
Read More
Tyler updates us on one more stock that reported earnings recently.
Read More
Tyler updates us on two more stocks that reported earnings recently.
Read More
We have four earnings reports from last night to get to today (ARNA, APPF, RPAY, SPT). Right now, I’m getting the first two out and will follow up with the other two shortly.
Read More
We are getting closer to clearing two of the biggest hurdles of uncertainty out there. I am, of course, talking about the U.S. presidential election and the Pfizer and BioNTech vaccine news.
Read More
Three of our portfolio stocks report earnings.
Read More
Two of our portfolio stocks report earnings.
Read More
Four of our portfolio stocks report earnings.
Read More
The market has started to look iffy lately and today we’re seeing another wave of selling. The pressure is on the bulls to step up and turn things around. Or, at least stop the bleeding. At the moment there are very few bright but...
Read More
Shares of one of our oldest positions are trading off more than 10% today after Bank of America analysts downgraded the stock to neutral from buy and trimmed their price target to 150 from 162.
Read More
This portfolio stock reported Q3 results this morning before the market opened. As expected, the company delivered outstanding results that surpassed expectations on both the top and bottom lines.
Read More
One of our portfolio stocks moves to Hold
Read More
Our latest addition reported first quarter of fiscal 2021 results last night that beat on the top line.
Read More
This portfolio stock reported Q2 results that came in better than expected on the top and bottom lines. Another stock moves to Hold.
Read More
This portfolio stock reported yesterday that Q2 revenue grew by 35% to $65.4 million (beating by $2.4 million) while adjusted EPS of $0.06 beat by $0.27.
Read More
Two portfolio stocks reported earnings recently and they both are still rated Buy.
Read More
Six portfolio stocks reported earnings recently.
Read More